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Abstract: Hypertension affects nearly one-third of all individuals in the US, yet one-half of all 
treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage 
of patients with uncontrolled BP is likely to be much higher when considering the number of 
patients who are not even aware of their hypertensive state. Elevated BP is associated with 
increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy 
is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need 
to be considered. Antihypertensive combination therapy, which may improve tolerability, offers 
the benefit of targeting different mechanisms of action. Numerous outcomes studies support the 
use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This 
review discusses the benefits of combination therapy with the angiotensin type II receptor blocker 
olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The 
pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support 
OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a 
rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based 
on pharmacokinetic differences, clinical concerns, and trends in use.
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Introduction
Hypertension, a highly prevalent condition that affects 29% of the population in the 
US,1 is a modifiable risk factor for cardiovascular (CV) morbidity and mortality, stroke, 
and renal failure.2 Indeed, there is a linear correlation between blood pressure (BP) and 
the risk of death from ischemic heart disease and stroke, regardless of age; this risk 
is doubled for each 20- or 10-mmHg increase in systolic BP (SBP) and diastolic BP 
(DBP), respectively.3 An increasing number of patients with hypertension in the US are 
receiving treatment. However, approximately 50% of patients receiving treatment fail 
to attain recommended BP goals of ,140/90 mmHg or ,130/80 mmHg for patients 
with diabetes mellitus or chronic renal disease.1 Current practice guidelines are based 
on clinical trial evidence, demonstrating that treating patients with hypertension to 
defined BP thresholds, or goals, improves long-term outcomes.3 Achieving BP control 
in a greater proportion of patients with hypertension will require treating more patients, 
treating them earlier, and intensifying their therapy when treatment goals are unmet.
An important component of ensuring successful treatment is the use of more aggres-
sive treatment strategies. BP goals are reached in only one-third of patients receiving 
monotherapy.4–6 As a result, combination therapy is required to achieve recommended Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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BP goals in the majority of patients with hypertension, 
particularly those with stage 2 hypertension, and treatment 
guidelines   emphasize the importance of starting antihyper-
tensive   combination therapy in patients with a BP level that 
exceeds the goal by .20/10 mmHg.3
Combination therapy should comprise different classes 
of agents with complementary mechanisms of action, which 
may provide an antihypertensive effect greater than either 
component alone, and with a favorable tolerability profile.3 
Blockade of the renin–angiotensin system (RAS) pathway 
by angiotensin type II receptor blockers (ARBs) provides an 
antihypertensive effect that can be enhanced by the addition 
of hydrochlorothiazide (HCTZ).7 HCTZ acts in the kidney 
by blocking the reabsorption of sodium and chloride in the 
distal portion of the kidney tubule.8 In addition, HCTZ is 
believed to have direct (vasodilation) or indirect effects 
on the blood vessel itself, although the exact mechanism 
explaining this is unknown.9 Use of HCTZ alone causes 
volume contraction that has been shown to cause an increase 
in RAS pathway activity to compensate.7 The synergistic 
addition of a RAS inhibitor to HCTZ blunts this physiological 
response to diuresis, thereby achieving volume contraction 
with decreased RAS activity.7
ARBs are a well tolerated drug class. Olmesartan 
medoxomil (OM) is a widely prescribed ARB that has 
been shown in some head-to-head studies to have greater 
BP-lowering efficacy than older ARBs such as losartan 
potassium (LOS),10,11 valsartan, and irbesartan.10 In a 12-week 
randomized, double-blind, forced-titration study, patients 
received LOS, OM, or valsartan.12 At week 8, reductions 
in seated cuff DBP (SeDBP) were significantly greater 
in the OM 40-mg group compared with the LOS group 
(100 mg once daily). By week 12, however, there were no 
significant differences in BP-lowering efficacy between OM 
(40 mg), valsartan (320 mg), and LOS (50 mg twice daily). 
In a subgroup analysis of this study in Black patients, OM 
demonstrated greater efficacy by week 8 compared with LOS; 
however, all drugs had similar antihypertensive effects by 
week 12.13 Recently, the newest member of the ARB family, 
azilsartan medoxomil, which has been approved for use in 
the US, has superior efficacy at its highest dose compared 
with OM and valsartan.14
Pharmacokinetic differences such as higher   angiotensin II 
receptor type 1 (AT1) receptor affinity, longer terminal 
elimination half-life, and slower AT1 receptor disassocia-
tion help contribute to the efficacy of OM.15,16 This article 
briefly reviews the efficacy and safety of combining the 
ARB OM with HCTZ in the management of hypertension 
and provides an update on current findings from recent 
clinical studies.
OM/HCTZ: pharmacokinetics  
and pharmacodynamics
OM is a prodrug that is hydrolyzed in the gastrointestinal tract 
to form its active metabolite, olmesartan.17 Once absorbed, the 
metabolite does not undergo further changes, and 35%–50% 
of the absorbed dose is excreted in the urine.17 Peak plasma 
concentrations are achieved in 1–2 hours, followed by an 
elimination half-life of 13 hours.17 Steady-state plasma con-
centrations are achieved in 3–5 days with once-daily dosing.17 
HCTZ is not metabolized and is rapidly eliminated by the 
kidney, with a plasma half-life between 5.6 and 14.8 hours.17 
No significant pharmacokinetic drug–drug interactions occur 
when OM and HCTZ are coadministered.18 The pharmacoki-
netics of OM 20 mg + HCTZ 25 mg in healthy subjects were 
similar to OM and HCTZ monotherapy at the same doses with 
regards to area underneath the concentration–time curve and 
maximum plasma concentration values at steady state and 
time to maximum plasma concentration values.18
OM selectively binds the AT1 receptor with high affinity, 
slow disassociation, and a high degree of insurmountable 
antagonism.15 OM is a more potent inhibitor of angiotensin II 
receptor binding than LOS and its active metabolite19 and 
dissociates from the receptor more slowly than telmisartan.15 
OM inhibits the pressor effects of angiotensin I at doses of 
2.5–40 mg; this inhibitory effect is dose-dependent.17 HCTZ 
combined with OM causes diuresis to begin within 2 hours 
of administration and peaks at approximately 4 hours, with 
a duration of 6–12 hours.17
Efficacy of OM and HCTZ 
combination therapy
Several studies have demonstrated the efficacy of OM + HCTZ 
for lowering BP and enabling the achievement of BP goals. 
A summary of OM + HCTZ efficacy studies are presented 
in Table 1.
In a multicenter, randomized, double-blind facto-
rial design study, 502 patients were assigned to pla-
cebo, OM monotherapy (10, 20, or 40 mg/day), HCTZ 
monotherapy (12.5 or 25 mg), and OM/HCTZ combina-
tion therapy (10/12.5, 10/25, 20/12.5, 20/25, 40/12.5,   
and 40/25 mg). All six combinations of OM + HCTZ pro-
duced statistically significant reductions in BP from baseline 
relative to placebo, and all OM + HCTZ combinations had 
greater BP reductions than their individual components.20 The 
BP reduction achieved at the maximum dose of OM/HCTZ Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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40/25 mg was 26.8/21.9 mmHg from a baseline BP of 
153.6/103.4 mmHg. This study reported individual SBP and 
DBP goals, and at the maximum OM/HCTZ 40/25 mg dose, 
87.2% achieved SBP ,140 mmHg, while 79.5% achieved 
DBP ,90 mmHg.20
A multicenter, double-blind study by Kereiakes et al 
randomized 191 patients with stage 2 hypertension to an 
OM + HCTZ or benazepril (BEN) + amlodipine (AML) 
combination treatment regimen for 12 weeks.21 Doses were 
up-titrated in a stepwise fashion from OM or BEN mono-
therapy if BP was $120/80 mmHg. Titration steps in the 
OM treatment group were OM 20 mg, OM 40 mg, OM/
HCTZ 40/12.5 mg, and OM/HCTZ 40/25 mg, while titration 
steps in the BEN treatment group were BEN 10 mg, BEN 
20 mg, BEN/AML 20/5 mg, and BEN/AML 20/10 mg. 
The OM + HCTZ treatment arm was associated with a 
greater reduction in SBP from baseline than BEN + AML at 
32.5 mmHg vs 26.5 mmHg (P , 0.024).21 A cumulative BP 
goal of ,140/90 mmHg was achieved by 66.3% of patients 
treated with OM + HCTZ compared with 44.7% of patients 
in the BEN + AML treatment arm (P , 0.006).21
The Benicar Efficacy: New Investigative Findings 
Showed Olmesartan Medoxomil Safely and Effectively 
Reduced Blood Pressure Compared With Placebo in a 
Clinical Evaluation of Patients With Stage 1 and Stage 
2   Hypertension (BENIFORCE) study was a 12-week, 
randomized, double-blind, placebo-controlled, titration study 
in 276 patients with stage 1 or stage 2 hypertension.22 Patients 
were randomized to placebo or an OM treatment regimen for 
a period of 12 weeks. If BP was $120/80 mmHg, patients 
were up-titrated in a stepwise fashion from monotherapy to 
a maximum of OM/HCTZ 40/25 mg. The titration steps were 
OM 20 mg, OM 40 mg, OM/HCTZ 40/12.5 mg, and OM/
HCTZ 40/25 mg. The OM-based treatment regimen provided 
significantly greater least-squares mean reductions in seated 
BP (SeBP) from baseline compared with placebo (22.3/12.1 
vs 0.1/−0.8 mmHg; P , 0.0001).22 The achievement rate   
of a cumulative BP goal of ,140/90 mmHg was significantly 
higher in OM-based treatment vs placebo recipients (74.1% 
vs 30.7%; P , 0.0001).22 Furthermore, BP normalization 
(,120/80 mmHg) was also achieved by more patients treated 
with the OM-based regimen vs placebo (27.3% vs 1.5%; 
P , 0.0001) (Figure 1).22 Recently, a subgroup analysis of 
BENIFORCE indicated that the significant improvements 
in BP lowering were achieved with OM-based therapy vs 
placebo, regardless of race, age, or sex (Figure 2).23
A recent European study investigated the safety and 
tolerability of OM/HCTZ in 1226 patients with stage 2 
hypertension.24 Patients entered an 8-week open-label 
period and were treated with OM 40 mg per day. Patients 
who failed to achieve BP control (trough seated cuff SBP 
[SeSBP] of 140–180 mmHg and SeDBP of 90–115 mmHg, 
Table 1 Clinical trials assessing the antihypertensive efficacy of OM/HCTZ combination therapy
Study Patients (N) Dosage (daily) Baseline SeBP  
(mmHg)
SeSBP/SeDBP reduction  
(mmHg)
% achieved  
SeBP target
 
Chrysant et al20
 
502
 
PLA 
OM 40 mg 
HCTZ 25 mg 
OM/HCTZ 40/25 mg
 
152.1/103.4 
152.9/102.6 
155.9/104.4 
153.6/103.4
 
3.3/8.2 
16.0/14.6 
17.1/12.9 
26.8/21.9
SeSBP , 140 mmHg 
33.3 
60.0 
67.4 
87.2
 
Kereiakes et al21
 
191
 
BEN/AML 20/10 mg 
OM/HCTZ 40/25 mg
 
169.6/101.4 
167.0/101.7
 
26.5/a 
32.5/a
SeBP , 140/90 mmHg 
44.7 
66.3
 
Oparil et al22
 
278
 
PLA 
OM/HCTZ 40/25 mg
 
155.3/93.7 
156.9/94.2
 
0.1/+0.8 
22.3/12.1
SeBP , 140/90 mmHg 
30.7 
74.1
 
Kereiakes et al38
 
178
 
OM/HCTZ 40/25 mg
 
165.5/87.7
 
25.4/10.5
SeBP , 140/90 mmHg 
67.0
 
 
Rump et al24
 
 
1226
 
 
OM/HCTZ 40/25 mg
 
 
155.4/98.0b
 
 
30.3/19.0
SeBP , 140/90 mmHg 
(,130/80 mmHg for T2DM) 
42.1
 
Kereiakes and 
Neutel40
 
192c
 
OM/HCTZ 40/25 mg
 
158.1/90.0
 
21.8/9.9
SeBP , 130/80 mmHg 
41.1
Notes: aDBP reductions not reported; bbaseline at end of OM 40 mg run-in period; call patients with T2DM.
Abbreviations: AML, amlodipine; BeN, benazepril; BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; PLA, 
placebo; SBP, systolic blood pressure; SeBP, seated cuff blood pressure; SeDBP, seated cuff diastolic blood pressure; SeSBP, seated cuff systolic blood pressure; T2DM, type 
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and mean 24-hour DBP $ 80 mmHg and $30% of   daytime 
DBP .85 mmHg) entered a randomized double-blind 
treatment phase of 8 weeks. Patients were randomized in 
a 2:2:2:1 scheme to OM 40 mg, OM/HCTZ 20/12.5 mg, 
OM/HCTZ 40/12.5 mg, and OM/HCTZ 40/25 mg. The 
primary endpoint was the change from baseline in SeDBP   
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Figure 1 Efficacy results from the BENIFORCE trial. (A) Mean change from baseline to week 12 or last observation carried forward in seated cuff BP by titration step in the 
total efficacy cohort.  (B) Proportion of patients who achieved BP ,140/90 mmHg in the total efficacy cohort.22
Note: *P , 0.05, †P , 0.01, ‡P , 0.001, §P , 0.0001 for within-group comparisons between study baseline and end of treatment using paired t-test. 
Reprinted from Oparil et al. J Clin Hypertens (Greenwich). 2008;10(12):911–921, with permission from John Wiley and Sons, copyright © 2008.
Abbreviations: BENIFORCE, Benicar Efficacy: New Investigative Findings Showed Olmesartan Medoxomil Safely and Effectively Reduced Blood Pressure Compared With 
Placebo in a Clinical evaluation of Patients with Stage 1 and Stage 2 Hypertension; BP, blood pressure; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SeDBP, 
seated cuff diastolic blood pressure; SeSBP, seated cuff systolic blood pressure.
0
10
< 140/90
BP goal (mmHg)
%
 
o
f
 
p
a
t
i
e
n
t
s
 
a
c
h
i
e
v
i
n
g
 
g
o
a
l
20
30
40
50
60
70
80
30.7
74.1
OM-based regimen
Placebo
90
100 B
from week 8 to the end of week 16. For the primary endpoint 
for the highest dosage of OM/HCTZ 40/25 mg, the change 
in SeDBP was −11.2 mmHg compared with −5.7 mmHg 
for patients who remained on OM 40 mg (P , 0.0001). The 
change in SeSBP for the same time period was −16.2 mmHg 
for OM/HCTZ 40/25 mg compared with −8.9 mmHg for OM Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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40 mg (P , 0.0001). The SeBP target of ,140/90 mmHg 
(,130/80 mmHg for patients with diabetes) was achieved 
by 42.1% of patients who received OM/HCTZ 40/25 mg 
compared with 24.8% of those treated with OM 40 mg.
Assessment of 24-hour ambulatory 
BP efficacy with OM/HCTZ 
combination in patients with 
difficult-to-treat hypertension
Two classes of patients with hypertension that is often 
difficult to treat are patients with type 2 diabetes   mellitus 
(T2DM) and the elderly. Diabetes mellitus affects an   
estimated 25.8 million US residents of all ages.25 T2DM is 
associated with higher risks of CV disease, nephropathy, and 
retinopathy – hard endpoints that are associated closely with 
BP control.3,25 It is recommended that patients with T2DM 
and hypertension be treated to a more aggressive BP goal 
of ,130/80 mmHg,26 which will often require two or more 
antihypertensive agents.3,27 In the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) trial, patients treated 
to an SBP of 119.3 mmHg required an average of 3.4 medi-
cations, while patients treated to an SBP ,133.3 mmHg 
required an average of 2.1 medications.28 The elderly are 
more likely to have treatment-resistant hypertension due to 
physiological changes in the arterial vasculature that occur 
naturally with aging.29 Hypertension is more prominent in 
the elderly than in any other age group, with an estimated 
prevalence of 65% in men and 75% in women.30 Treating BP 
in the elderly has been associated with decreased incidence 
of various CV endpoints.3,31
BP naturally fluctuates and exhibits a diurnal variation 
over a 24-hour period.32 In the morning hours, CV events 
are more common due to a morning surge in BP.33 This 
increase in BP towards the end of the sleep period may be 
related to circadian upregulation of the RAS during the   
nighttime.34 Ambulatory BP monitoring (ABPM) can pro-
vide clinicians with additional information to diagnose 
hypertension, make more informed treatment decisions, 
and to gauge the effectiveness of antihypertensive therapy 
over 24 hours.35–37 BP control over a 24-hour dosing period 
has been demonstrated in several efficacy studies with 
OM + HCTZ.38,39
Patients with T2DM:  
the BeNIFICIARY trial
The BENIcar safety and efFICacy evaluatIon: an open-label, 
single-ARm, titration study in patients with hypertension and 
tYpe 2 diabetes (BENIFICIARY) study assessed 24-hour BP   
control in patients initiated on OM 20 mg up-titrated to OM 
40 mg, OM/HCTZ 40/12.5 mg, and OM/HCTZ 40/25 mg if 
BP was $120/70 mmHg.39 ABPM was   performed at baseline 
and at the end of week 12. The primary endpoint was the 
change from baseline in mean 24-hour ambulatory SBP at 
week 12. At 12 weeks, 24-hour ambulatory BP was reduced 
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Figure 2 Results of a subgroup analysis of the BENIFORCE trial that reported the LS mean changes from baseline in SeBP in patients stratified according to sex, age, and race.23
Notes: aP , 0.0001 vs placebo; bP , 0.05 vs placebo; cP , 0.001 vs placebo.
Abbreviations: BENIFORCE, Benicar Efficacy: New Investigative Findings Showed Olmesartan Medoxomil Safely and Effectively Reduced Blood Pressure Compared With 
Placebo in a Clinical evaluation of Patients with Stage 1 and Stage 2 Hypertension; LS, least-squares; SeBP, seated cuff blood pressure; SeDBP, seated cuff diastolic blood 
pressure; SeSBP, seated cuff systolic blood pressure.
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by 20.4/11.1 mmHg (P , 0.0001 vs baseline), and ambulatory 
BP targets of ,130/80, ,125/75, and ,120/80 mmHg were 
achieved by 61.6%, 47.1%, and 39.0% of patients, respec-
tively (Figure 3).39 Of special interest is that BP control was 
maintained during the last 6, 4, and 2 hours of the dosing 
interval when the normal morning rise in BP occurred.39 The 
SeBP reduction from baseline was 21.8/9.9 mmHg in patients 
titrated to OM/HCTZ 40/25 mg intensified, and 41.1% of 
patients achieved the cumulative guideline-recommended 
BP goal of ,130/80 mmHg.40
elderly patients: the BeniSILveR trial
The Benicar Efficacy: New Investigation Shows Olmesartan 
Medoxomil Treatment Increasingly Leads Various Elderly 
Populations to Safe BP Reductions (BeniSILVER) study was 
a 12-week, open-label, multicenter trial.38 This study was con-
ducted in 178 patients aged $65 years, and similar to BENIFI-
CIARY, patients were initiated on OM 20 mg and up-titrated 
to OM/HCTZ 40/25 mg in a stepwise fashion if SeBP was 
$120/70 mmHg. The primary endpoint was the change in mean 
24-hour ambulatory SBP from baseline to week 12. At study end, 
mean 24-hour ambulatory BP decreased by 25.7/12.3 mmHg 
(P , 0.0001 vs baseline) (Figure 4) from a mean baseline BP of 
148.8/80.9 mmHg.38 After 12 weeks, the achievement of 24-hour 
ambulatory BP targets was also assessed in this study. Twenty-
four hour ambulatory BP targets of ,130/80, ,125/75, and 
,120/80 mmHg were achieved by 73.3%, 56.7%, and 44.0% 
of patients, respectively.38 BP control was maintained through-
out the 24-hour dosing interval with significant BP reductions 
from baseline observed during the last 6, 4, and 2 hours before 
re-dosing (P , 0.0001). A subgroup analysis in patients aged 
.75 years showed that 24-hour ambulatory BP targets of 
,130/80, ,125/75, and ,120/80 mmHg were achieved by 
67.5%, 52.5%, and 40.0% of patients, respectively.41 Based on 
these results, a treatment algorithm using OM ± HCTZ appears 
to be effective in providing 24-hour BP control in a range of 
patients with hypertension, including those with T2DM and 
the elderly. There is currently no consensus on ambulatory BP 
goal values; however, the American Heart Association recom-
mends normal 24-hour, daytime, and nighttime ambulatory BP 
values in adults of ,130/80, ,135/85, and ,120/70 mmHg,   
respectively.42
Safety and tolerability of OM  
and HCTZ
A fixed-dose combination of OM + HCTZ is associated 
with an overall adverse event (AE) rate that is similar to 
placebo, including when race or sex are considered.43 AEs 
23 22 21 20 19 18 17 16 15 14 13 12 11
Time (hours)
H
o
u
r
l
y
 
m
e
a
n
 
S
B
P
 
a
n
d
 
D
B
P
 
(
m
m
H
g
)
10 9 8
Dose
Administration
7 6 5 4 3 2 1 0
40
60
80
100
120
140
160 SBP baseline SBP end of study DBP baseline DBP end of study
Figure 3 Hourly mean ambulatory blood pressure at baseline and end of study (week 12) in patients with diabetes treated with an olmesartan medoxomil/hydrochlorothiazide-
based algorithm in the BeNIFICIARY study.39
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that occurred at a higher frequency than placebo in .2% of 
patients in pivotal trials include dizziness, upper respiratory 
tract infection, hyperuricemia, and nausea.43 Lending fur-
ther support to placebo-like tolerability of OM + HCTZ are 
safety data reported in the BENIFORCE and BENIFICIARY 
trials. In BENIFORCE, the incidence of at least one AE 
across titration steps in the OM + HCTZ treatment arm 
ranged from 15.9% to 28.4% compared with 15.9%–26.2% 
during the placebo run-in period.22 Drug-related AEs ranged 
from 2.2% to 7.6% across titration steps in the OM + HCTZ 
treatment arm compared with 2.1%–9.5% in the placebo 
arm. Most adverse effects were mild to moderate in inten-
sity, with   dizziness being the most commonly reported AE 
at 3.4%.22 In the randomized double-blind period of the 
European study, treatment-emergent AEs (TEAEs) occurred 
in 11.8%–15.3% of patients across the treatment groups.24
In the BENIFICIARY study, where all patients had T2DM, 
the incidence of one or more TEAE was 13.5%–25.7% across 
all titrations steps, slightly lower than in BENIFORCE.39 
Drug-related TEAEs ranged from 0.5% to 7.6% across 
the titration steps. The most commonly reported TEAE in 
BENIFICIARY was arthralgia and extremity pain at 2.1%.39 
The occurrence of dizziness reported in BENIFICIARY was 
lower than in BENIFORCE at 0.7%.39
The treatment of hypertension in the elderly may result 
in relatively large BP reductions, especially in SBP. These 
large SBP reductions may be associated with dizziness and 
hypotension. In the BeniSILVER study, conducted in patients 
aged .65 years, 32.6% of patients reported an AE during 
the entire 12-week active treatment period, of which 11.8% 
were drug related.38 Incidences of drug-related dizziness and 
hypotension were 3.4% and 2.2%, respectively.
The use of HCTZ as monotherapy has been associated 
with hypokalemia, hyponatremia, hyperuricemia, and 
elevated blood glucose.44 In a study by Izzo et al, the 
maximum dose of OM/HCTZ 40/25 mg was not found to be 
associated with clinically significant decreases in sodium or 
potassium.45 Glucose and uric acid levels were found to be 
increased, with a mean uric acid level of 7.38 mg/dL (baseline 
value = 6.03 mg/dL) and mean glucose value of 109.0 mg/dL 
(baseline value = 103.9 mg/dL).45 These were within normal 
limits and were not clinically significant events associated 
with these laboratory elevations.45
Benefits beyond BP
A number of ARBs have demonstrated the potential to provide 
benefits beyond their BP-lowering effects. In the Losartan 
Intervention for Endpoint Reduction (LIFE) trial, LOS 
monotherapy at 50 mg up-titrated to LOS 100 mg + HCTZ 
25 mg over a period of 4 years resulted in a statistically signifi-
cant decrease in the secondary endpoint of new-onset diabetes 
when compared with an atenolol + HCTZ   regimen (13.0 vs 
17.4 events/1000 patient-years; P = 0.001).46 Beneficial effects 
of an ARB + HCTZ combination on the rate of new-onset   
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diabetes were also demonstrated in the Valsartan Antihyperten-
sive   Long-term Use Evaluation (VALUE) trial. Patients titrated 
to a maximum dose of valsartan 160 mg + HCTZ 25 mg had 
significantly fewer events of new-onset diabetes compared 
with an AML treatment regimen over a period of 4 years (32.1 
vs 41.1 events/1000 patient-years; P , 0.0001).47 New-onset 
diabetes was also a secondary endpoint in the VALUE trial. In 
the Randomized Olmesartan and Diabetes Microalbuminuria 
Prevention (ROADMAP) study, 4447 patients with T2DM 
were assigned to either OM 40 mg or placebo for a median 
of 3.2 years. Additional drugs (but not angiotensin-converting 
enzyme inhibitors or ARBs) were used as necessary to attain 
BP control (,130/80 mmHg).48 The primary endpoint was 
the time to onset of microalbuminuria (MA). Overall, MA 
occurred in 8.2% of the OM group compared with 9.8% of the 
placebo group. The median time to onset of MA was 576 days 
for placebo compared with 722 days for OM (hazard ratio: 
0.77; P = 0.01), a risk reduction of 23%. Although no other 
study with ARBs has yielded similar results, ROADMAP 
provides evidence that pharmacological blockade with the 
ARB OM is highly effective in reducing the risk of developing 
MA and that the effect can be achieved through BP-dependent 
and BP-independent effects.49
Rationale for combinations  
of HCTZ and OM
Fixed-dose antihypertensive drug combination therapies that 
include a diuretic usually contain HCTZ rather than other 
agents such as chlorthalidone. Data reported by the Veterans 
Administration (VA) Cooperative study in 1967 is an early 
example whereby HCTZ demonstrated BP-reducing efficacy 
as well as reductions in CV events.50 In a cohort of high-
risk male patients with DBP of 115–129 mmHg (N = 143), 
HCTZ combined with reserpine and hydralazine reduced BP 
by an average of 43/30 mmHg after 24 months of treatment, 
and resulted in significantly reduced CV events compared 
with placebo (2 vs 27 total events; P , 0.001). Three years 
later, the VA Cooperative Study reported data in a cohort 
of 380 male patients with lower risk diastolic hypertension   
(90–114 mmHg).51 An average reduction in BP of 27/17 mmHg 
was achieved after 4 months of combination therapy. The esti-
mated 5-year risk of a morbid event was reduced with HCTZ-
based treatment compared with placebo (18% vs 55%).
The preference for HCTZ over chlorthalidone may also 
be due to concerns about hypokalemia with chlorthalidone;52 
however, hypokalemia is a class-wide effect for diuretics.53 
The Multiple Risk Factor Intervention Trial (MRFIT) was a 
randomized primary prevention trial in 12,866 high-risk men 
with hypertension that compared a special intervention (SI) 
program (stepped-care combination therapy, smoking   cessation 
counseling, and dietary advice) with usual care (UC) available 
within the community.54 Stepped-care therapy in the SI program 
began with a choice of HCTZ or chlorthalidone based on the 
preference at each treatment center. Reserpine, hydralazine, and 
guanethidine were able to be added on to the choice of diuretic, 
if required, to bring patients to the goal DBP of ,90 mmHg. 
After 7 years of follow-up, a statistically nonsignificant dif-
ference of 7.1% in mortality from coronary heart disease 
(CHD) was observed in the SI care group compared with 
UC. Of interest, with regards to hypokalemia, was a finding 
in predefined subgroups that hypertensive men with baseline 
echocardiogram abnormalities had higher CHD mortality in 
the SI group compared with UC (36 vs 21 CHD deaths). This 
has led some to be concerned about the role that the choice of 
diuretics may have played in the increased mortality within this 
subgroup, particularly with regards to chlorthalidone.
In a study of 233 hypertensive men, Siegel et al sought 
to determine the potassium-wasting effects of HCTZ at 
50 mg/day, with and without potassium supplementation, 
or triamterene against chlorthalidone 50 mg and placebo.55 
After 2 months of treatment, serum potassium levels were 
decreased to ,3.5 mmol/L (threshold of hypokalemia) in 
15% of patients treated with HCTZ 50 mg without potassium 
supplementation vs 33% of patients treated with chlorthal-
idone 50 mg (P , 0.01).55 Severe hypokalemia, defined as 
serum potassium levels ,3.0 mmol/L, occurred in 10% of 
patients taking HCTZ without supplementation and 20% of 
patients taking chlorthalidone, which was not a statistically 
significant difference.55 However, the dosage of HCTZ that 
was used in the study was greater than the maximum dosage 
(25 mg) used in single-pill combination formulations.
Pharmacokinetic considerations also inform the ratio-
nale for using HCTZ over chlorthalidone. Chlorthalidone 
has an estimated half-life ranging from 40 to 72 hours,52 
while HCTZ has a half-life ranging from 6 to 15 hours.44 In 
select patient populations with renal impairment, avoiding 
medications with long half-lives may help to reduce 
the likelihood of AEs. Drug labels for both HCTZ and 
chlorthalidone advise against administering to patients with 
renal impairment, and neither diuretic appears in the Beers   
criteria for inappropriate medication use in the elderly.56 The 
shorter half-life of HCTZ could potentially be a concern with 
regards to 24-hour BP control. However, the antihypertensive 
efficacy of OM/HCTZ combination therapy has been shown 
to be maintained throughout the 24-hour dosing interval in 
a variety of patient subgroups.57Integrated Blood Pressure Control 2011:4 submit your manuscript | www.dovepress.com
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Data from the ALLHAT study suggest that chlorthalidone 
may increase the incidence of new-onset diabetes.58 When 
compared with AML and lisinopril, chlorthalidone-treated 
patients had 43% and 65% higher incidences of new-onset 
diabetes, respectively.58 While there were no differences 
between chlorthalidone and AML or lisinopril in CV out-
comes, the trial duration would not have been long enough 
to account for CV outcomes in patients with new-onset dia-
betes, as CV effects would not become manifest in the short 
timeframe of the study.58 Head-to-head outcomes studies 
between chlorthalidone and HCTZ have not been conducted, 
and thus it remains to be seen whether HCTZ would have 
had similar increases in new-onset diabetes.
An ABPM substudy of the Avoiding Cardiovascular 
Events through Combination Therapy in Patients Living with 
Systolic Hypertension (ACCOMPLISH) trial was recently 
conducted to identify any differences in 24-hour BP con-
trol between BEN plus AML and BEN plus HCTZ after 2 
years of treatment.59 Mean 24-hour, daytime, and nighttime 
BP values were not significantly different between the two 
treatment groups (Figure 5); BP control rates were .80% 
in both groups.59 This indicates that 24-hour BP control is 
similar between the two treatment groups and supports the 
original conclusions of the ACCOMPLISH investigators that 
the improvement in CV outcomes seen in the AML-based 
regimen is most likely due to other putative cardioprotective 
properties of combining a RAS blocker with AML.60 AML 
has a terminal elimination half-life ranging from 30 to 
50 hours,61 very similar to chlorthalidone; however, the 
longer half-life conferred no additional benefit over HCTZ 
with regards to 24-hour BP control.59
The overall preference of HCTZ over chlorthalidone may 
simply be due to the availability of HCTZ as a component 
of fixed-dose, single-pill combinations. There are currently 
no fixed-dose ARB + chlorthalidone single-pill combination 
products available.
In view of the recent clinical evidence that demonstrates 
the efficacy and safety of treatment regimens based on 
OM + HCTZ, there is no reason that HCTZ should not remain 
as a preferred treatment option for use in combination with 
ARBs such as OM. However, there remains an unmet need 
for head-to-head outcomes studies that compare the relative 
efficacy and tolerability of HCTZ and chlorthalidone in order 
to provide evidence for informing clinical guidelines.53
Conclusion
ARBs provide excellent efficacy and tolerability and are 
frequently used as first-line therapy, alone or in combina-
tion with diuretics. The combination of OM/HCTZ has been 
shown to be an effective and well tolerated treatment option 
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that provides BP-lowering efficacy and improvements in BP 
control in patients with hypertension. BP reduction achieved 
through combination therapy has been associated with 
improvements in CV morbidity and mortality.62 The clinical 
evidence discussed in this review provides a rationale for the 
use of OM/HCTZ combination therapy as an antihypertensive 
treatment strategy, regardless of patient age, sex, or race, or 
patients with common comorbidities such as diabetes.
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